Can Synjardy (empagliflozin and metformin) cause gastrointestinal (GI) upset?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Does Synjardy Cause GI Upset?

Yes, Synjardy (empagliflozin/metformin combination) commonly causes gastrointestinal upset, primarily due to its metformin component, which produces GI side effects in approximately 50% of patients. 1, 2

Primary Source of GI Side Effects

The metformin component is responsible for virtually all GI adverse effects associated with Synjardy:

  • Common GI symptoms include diarrhea, nausea, abdominal pain, flatulence, bloating, and vomiting 1, 3, 4
  • These symptoms are dose-dependent and occur in approximately 50% of patients taking metformin 2
  • The empagliflozin component does not typically cause GI upset 1

Timing and Pattern of GI Side Effects

Early-Onset Symptoms

  • Most GI symptoms occur during initial treatment and are typically transient, resolving with continued therapy 4, 2
  • Symptoms usually appear during dose titration and improve over time 1

Late-Onset Symptoms

  • GI side effects can occur even after years of stable metformin therapy, which is often under-recognized and misdiagnosed 5, 6
  • Late-onset chronic diarrhea has been documented after several years of stable treatment 5, 6

Mitigation Strategies

Initial Dosing Approach

  • Start metformin at 500 mg once daily with food and increase by 500 mg every 1-2 weeks 4
  • Slow titration significantly reduces the incidence and severity of GI symptoms 1, 3
  • Taking medication with meals helps minimize adverse effects 3

Formulation Considerations

  • Extended-release metformin formulations reduce GI side effects compared to immediate-release preparations 4, 7
  • In patients switched from immediate-release to extended-release metformin, GI adverse events decreased from 26.34% to 11.71% (p=0.0006) 7
  • Diarrhea specifically decreased from 18.05% to 8.29% (p=0.0084) after switching to extended-release formulation 7

When Symptoms Persist

  • Temporarily reduce the dose or discontinue metformin if patients experience persistent nausea, vomiting, or dehydration 4
  • Consider a drug-free interval before pursuing extensive diagnostic workup, even with long-term stable dosing 5
  • Dose reduction or elimination may be necessary for persistent GI side effects that don't resolve 3, 4

Clinical Pitfalls

Misdiagnosis Risk

  • Metformin-induced chronic diarrhea is frequently misdiagnosed as irritable bowel syndrome or other primary GI disorders 6
  • Always consider metformin as the cause before ordering expensive diagnostic tests in diabetic patients with chronic diarrhea 5, 6

Important Contraindications

  • Discontinue metformin immediately if eGFR <30 mL/min/1.73 m² and consider dose reduction when eGFR <45 mL/min/1.73 m² 1, 4
  • Stop metformin during severe illness, vomiting, or dehydration to prevent lactic acidosis 1, 3

Additional Monitoring

  • Monitor vitamin B12 levels periodically with long-term metformin use, checking annually 3, 4
  • Vitamin B12 deficiency can worsen peripheral neuropathy symptoms 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Study of Diversity of Metformin Related Gastrointestinal Side Effects.

The Journal of the Association of Physicians of India, 2020

Guideline

Metformin Therapy Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Managing Metformin-Associated GI Symptoms

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.